Dextromethorphan
- Generic Name
- Dextromethorphan
- Brand Names
- Auvelity, Benylin DM, Bromfed DM, Broncotron, Cepacol Sore Throat Plus Cough, Cheracol D, Children's Nyquil Cold and Cough, Chloraseptic Sore Throat + Cough, Coricidin Hbp Chest Congestion, Coricidin Hbp Cough and Cold, Creomulsion, DM, Dayquil Cough, Delsym, Delsym Cough Plus Chest Congestion DM, Delsym Cough Plus Soothing Action, Delsym Cough Relief Plus Soothing Action, Despec Reformulated Jun 2008, Diabetic Tussin DM, Dimetapp Long Acting Cough Plus Cold, Diphen, G-zyncof, Mucinex Children's Cough, Mucinex Cough, Mucinex DM, Nuedexta, Nyquil Cough, Pediacare Children's Cough and Congestion, Promethazine DM, Robafen Cough, Robafen DM, Robitussin 12 Hour Cough Relief, Robitussin Cough & Congestion, Robitussin Maximum Strength Cough Plus Chest Congestion DM, Robitussin Nighttime Cough DM, Robitussin Pediatric Cough & Cold LA, Robitussin Pediatric Cough Suppressant, Safetussin DM, Safetussin PM, Scot-tussin DM, Scot-tussin Diabetic CF, Scot-tussin Sugar Free DM, Sudafed PE Children's Cold & Cough, Triaminic Day Time Cold & Cough, Tusnel Diabetic
- Drug Type
- Small Molecule
- Chemical Formula
- C18H25NO
- CAS Number
- 125-71-3
- Unique Ingredient Identifier
- 7355X3ROTS
- Background
Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors.
Dextromethorphan was granted FDA approval before 3 December 1957.
- Indication
Dextromethorphan is indicated in combination with brompheniramine and pseudoephedrine in the treatment of coughs and upper respiratory symptoms associated with allergies or the common cold. Dextromethorphan is also used in combination with guaifenesin as an over-the-counter product to relieve a cough. Dextromethorphan in combination with quinidine is indicated in the treatment of pseudobulbar affect.
- Associated Conditions
- Allergic cough, Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Allergies, Coughing caused by Bronchitis, Coughing caused by Flu caused by Influenza, Fever, Flu caused by Influenza, Headache, Irritative cough, Itching of the nose, Itching of the throat, Major Depressive Disorder (MDD), Nasal Congestion, Pseudobulbar Affect (PBA), Rhinorrhoea, Sneezing, Cold or flu syndrome, Upper respiratory symptoms, Watery itchy eyes
- Associated Therapies
- Airway secretion clearance therapy, Bronchodilation, Oropharyngeal antisepsis
A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
- Conditions
- Drug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Allyx Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT06632990
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism
- Conditions
- Drug Interaction
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06566794
- Locations
- 🇫🇮
Department of Clinical Pharmacology, Helsinki, Finland
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
- Conditions
- Hodgkin LymphomaNon Hodgkin Lymphoma
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06383338
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 72
- Registration Number
- NCT06348290
Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Saddle Block
- Conditions
- Regional Anesthesia Morbidity
- Interventions
- Drug: FENT group
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Zulekha Hospitals
- Target Recruit Count
- 58
- Registration Number
- NCT06216197
- Locations
- 🇪🇬
Al-Azhar faculty of medicine, Cairo, Egypt
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
- Conditions
- Trypanosomiasis, African
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 20
- Registration Number
- NCT05947604
- Locations
- 🇲🇾
Clinical Research Center (CRC) Ampang Hospital, Kuala Lumpur, Malaysia
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
- Conditions
- Treatment Resistant Schizophrenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Target Recruit Count
- 40
- Registration Number
- NCT05944510
- Locations
- 🇮🇳
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India
A Study of IBI351 in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05699993
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Drug Interaction Study of LY3871801 in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT05602675
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- The Guthrie Clinic
- Target Recruit Count
- 104
- Registration Number
- NCT05590923
- Locations
- 🇺🇸
Robert Packer Hospital, Sayre, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.